<DOC>
	<DOCNO>NCT02673138</DOCNO>
	<brief_summary>This study open-label , cross-over study subject study study condition - suspension subcutaneous insulin infusion via pump treatment insulin alone ( control ) vs. suspension subcutaneous insulin via pump treatment insulin canagliflozin .</brief_summary>
	<brief_title>Effect Canagliflozin T1DM ( Type 1 Diabetes Melitus ) After Interruption Continuous Subcutaneous Insulin Infusion</brief_title>
	<detailed_description>The study consist 4 visit : enrollment/screening visit , control visit pump suspension prior treatment canagliflozin , visit pump suspension canagliflozin end study visit . Each pump suspension visit approximately 20-hour overnight admission Hospital Research Unit ( HRU ) .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>1 . Age 1845 year 2 . Clinical diagnosis T1D ( type 1 diabetes ) ( formal antibody and/or genetic testing require ) 3 . Duration T1D ≥ 1 year 4 . HbA1c ≤ 9 % 5 . Treated continuous subcutaneous insulin infusion ( without adjunctive treatment SGLT2 inhibitor ) least 3 month 6 . Body weight &gt; 40 kg 7 . Be good general health without acute chronic illness judgment investigator could interfere study jeopardize subject safety 8 . Normal hematocrit 9 . Able give consent 10 . Female subject reproductive potential must abstinent consistently use appropriate family planning method . 1 . Insulin resistant ( define require &gt; 1.5 units/kg/day time study enrollment ) 2 . Renal impairment , determine eGFR &lt; 60 ml/minute/1.73m2 1 . History unstable rapidly progress renal disease 2 . Conditions congenital renal glucosuria 3 . Renal allograft 4 . Recurrent UTI ( urinary tract infection ) 5 . History Vesicoureteralreflux disease 3 . Presence medical psychiatric disorder may interfere subject safety study conduct 4 . Use metformin , thiazolidinedione GLP1 agonist within 1 month prior screen visit . For subject canagliflozin SGLT2 inhibitor , alternate study procedure may utilize describe 5 . Use medication ( besides insulin SGLT2 inhibitor ) know effect blood glucose level , include oral systemic glucocorticoid therapy . Inhaled , intranasal , rectal corticosteroid use allow long give within 2 week close loop admission . Use topical glucocorticoid allowable long affected skin area overlap study device sit 6 . History hypoglycemic seizure within last 3 month 7 . History diabetic ketoacidosis ( DKA ) require medical intervention ( ie . emergency room visit and/or hospitalization ) within 1 month prior screen visit 8 . Allergies contraindication content canagliflozin tablet insulin 9 . Volume deplete subject . Subjects risk volume depletion due coexist condition concomitant medication , loop diuretic carefully monitor volume status exclude study 10 . Female subject pregnant , lactating , unwilling test pregnancy 11 . Recurrent GU ( genitourinary ) infection 12 . Uncircumcised male secondary increase risk development GU infection 13 . History hypotension , define blood pressure ( BP ) &lt; 10th % age sex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>